24
19
1
49
2
2
2c
1b
1d
18
39
63
1d
2 29
1d
25
Andrew H Matthews, MD, MSCE
88
63
Assistant Professor of Clinical Medicine (Hematology-Oncology)
7
5f
Department: Medicine
4
1
b
1d
46
Contact information
53
4
3
3
3
2
4
b
1f
53
Perelman Center for Advanced Medicine
34 12 South Pavilion
Philadelphia, PA 19104
26
34 12 South Pavilion
Philadelphia, PA 19104
35
f
13
Education:
21 7 BA 4e (Biology, Molecular Biology, Economics, Business and Public Policy) c
34 University of Pennsylvania , 2009.
21 7 MD 15 (Medicine) c
53 Sidney Kimmel Medical College, Thomas Jefferson University, 2016.
21 9 MSCE c
57 Perelman School of Medicine at the University of Pennsylvania , 2022.
c
3
3
3
3
8d
Permanent link21 7 BA 4e (Biology, Molecular Biology, Economics, Business and Public Policy) c
34 University of Pennsylvania , 2009.
21 7 MD 15 (Medicine) c
53 Sidney Kimmel Medical College, Thomas Jefferson University, 2016.
21 9 MSCE c
57 Perelman School of Medicine at the University of Pennsylvania , 2022.
c
2 29
21
1e
1d
24
2b
29
27
23
18a Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9(3): 533-544, Feb 2025.
1b3 Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 114(4): 626-635, Dec 2024.
1b7 Takeshi Onoue, Andrew H Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M Smith, Shannon R McCurdy, Michael G Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie: Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines. Cardio-Oncology 10(1), Nov 2024 Notes: DOI: 10.1186/s40959-024-00275-5.
24f Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander E Perl, David L Porter, Arlene Zeringue, Joseph H Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia. Haematologica 8(109): 2732-2737, Aug 2024.
108 Laczko D, Poveda-Rogers C, Matthews AH, Snaith O, Luger S, Bagg A, Caponetti GC, Morrissette JJD, Yang G.: RAD21 mutations in acute myeloid leukemia. Leuk & Lymphoma 65(7): 958-964, Jul 2024.
129 Matthews A, Fenu E, Skuli SJ, Harris JC, Lai C.: Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. Leuk & Lymphoma 65(7): 1012-1015, Jul 2024.
1b3 Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 114(4): 626-635, Apr 2024.
1ef Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK.: Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers. Am J Hematol 99(4), Feb 2024.
1da Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW.: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol 98(8): 1254-1264, Aug 2023.
2c
7
1d
1f
Selected Publications
29f Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M.: Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia Jul 2025.18a Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9(3): 533-544, Feb 2025.
1b3 Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 114(4): 626-635, Dec 2024.
1b7 Takeshi Onoue, Andrew H Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M Smith, Shannon R McCurdy, Michael G Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie: Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines. Cardio-Oncology 10(1), Nov 2024 Notes: DOI: 10.1186/s40959-024-00275-5.
24f Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander E Perl, David L Porter, Arlene Zeringue, Joseph H Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia. Haematologica 8(109): 2732-2737, Aug 2024.
108 Laczko D, Poveda-Rogers C, Matthews AH, Snaith O, Luger S, Bagg A, Caponetti GC, Morrissette JJD, Yang G.: RAD21 mutations in acute myeloid leukemia. Leuk & Lymphoma 65(7): 958-964, Jul 2024.
129 Matthews A, Fenu E, Skuli SJ, Harris JC, Lai C.: Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. Leuk & Lymphoma 65(7): 1012-1015, Jul 2024.
1b3 Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 114(4): 626-635, Apr 2024.
1ef Abaza Y, Winer ES, Murthy GSG, Shallis RM, Matthews AH, Badar T, Geramita EM, Kota VK, Swaroop A, Doukas P, Bradshaw D, Helenowski IB, Liu Y, Zhang H, Im A, Litzow MR, Perl AE, Atallah E, Altman JK.: Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers. Am J Hematol 99(4), Feb 2024.
1da Matthews AH, Perl AE, Luger SM, Gill SI, Lai C, Porter DL, Skuli S, Bruno XJ, Carroll MP, Freyer CW, Carulli A, Babushok DV, Frey NV, Hexner EO, Martin ME, McCurdy SR, Stadtmauer EA, Loren AW, Paralkar VR, Maillard IP, Pratz KW.: Real-world effectiveness of intensive chemotherapy with 7&3 versus venetoclax and hypomethylating agent in acute myeloid leukemia. Am J Hematol 98(8): 1254-1264, Aug 2023.
2c
44
23
Back to Top
1b
1d
18